Loading...
Market
Will the FDA approve stem cell therapy for HIV using wildtype CCR5 cells by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and website
Story
NatureMedicine: Patient Achieves HIV Remission with Wildtype CCR5 Stem Cells
Sep 5, 2024, 06:30 PM
A male patient has achieved durable HIV remission after receiving an allogenic hematopoietic stem cell transplant from a donor with wildtype CCR5 cells, according to a case study by NatureMedicine. This marks the first remission with wildtype CCR5 cells. The case study highlights the potential of using stem cells from individuals who naturally lack CCR5 receptors to cure HIV. This development follows controversial research by He Jiankui, a Chinese professor who used CRISPR to edit the genomes of two babies to provide them with natural resistance to HIV, which raised significant ethical concerns.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes, in the USA • 25%
Yes, in Europe • 25%
Yes, in Asia • 25%
No • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Gilead Sciences • 25%
Other • 25%